American Vanguard (AVD) 10-Q 1 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 25, 2013
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'AVD	'
Entity Registrant Name	'AMERICAN VANGUARD CORP	'
Entity Central Index Key	'0000005981	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	28,660,282

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net sales	$97,201	$89,836	$305,499	$261,928
Cost of sales	54,042	50,211	166,493	146,579
Gross profit	43,159	39,625	139,006	115,349
Operating expenses	28,025	26,460	84,823	73,540
Operating income	15,134	13,165	54,183	41,809
Interest expense	464	701	1,712	2,157
Interest capitalized	-20	-165	-245	-313
Income before provision for income taxes and loss on equity investment	14,690	12,629	52,716	39,965
Income tax expense	5,559	4,553	18,500	14,411
Income before loss on equity investment	9,131	8,076	34,216	25,554
Loss from equity method investment	386	'	386	'
Net income	8,745	8,076	33,830	25,554
Net loss attributable to non-controlling interest	125	'	341	'
Net income attributable to American Vanguard	8,870	8,076	34,171	25,554
Change in fair value of interest rate swaps	133	41	485	87
Foreign currency translation adjustment	-126	306	-195	428
Comprehensive income	$8,877	$8,423	$34,461	$26,069
Earnings per common share-basic	$0.31	$0.29	$1.21	$0.92
Earnings per common share-assuming dilution	$0.31	$0.28	$1.18	$0.89
Weighted average shares outstanding-basic	28,322	27,970	28,295	27,818
Weighted average shares outstanding-assuming dilution	28,889	28,878	28,890	28,673

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash	$12,325	$38,476
Receivables:	'	'
Trade, net of allowance for doubtful accounts of $543 and $623, respectively	109,318	76,073
Other	2,489	1,230
Receivables,net	111,807	77,303
Inventories	127,172	87,951
Prepaid expenses and other short-term assets	12,381	13,710
Deferred income tax assets	4,877	4,877
Total current assets	268,562	222,317
Property, plant and equipment, net	51,642	45,701
Intangible assets, net of applicable amortization	108,641	113,521
Other assets	34,569	18,351
Total assets	463,414	399,890
Current liabilities:	'	'
Current installments of long-term debt	71	16,247
Current installments of other liabilities	1,635	1,839
Accounts payable	32,764	32,838
Deferred revenue	393	20,427
Accrued program costs	95,722	32,335
Accrued expenses and other payables	11,271	8,671
Income taxes payable	736	1,313
Total current liabilities	142,592	113,670
Long-term debt, excluding current installments	38,894	36,196
Other liabilities, excluding current installments	3,932	5,425
Deferred income taxes	19,163	19,163
Total liabilities	204,581	174,454
Commitments and contingent liabilities	'	'
Stockholders' equity:	'	'
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued	'	'
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 30,997,686 shares at September 30, 2013 and 30,766,730 shares at December 31, 2012	3,100	3,077
Additional paid-in capital	58,181	54,323
Accumulated other comprehensive loss	-1,472	-1,762
Retained earnings	203,610	174,243
Total stockholders' equity including treasury stock	263,419	229,881
Less treasury stock, at cost, 2,310,634 shares at September 30, 2013 and at December 31, 2012	-4,804	-4,804
American Vanguard stockholders' equity	258,615	225,077
Non-controlling interest	218	359
Total stockholders' equity	258,833	225,436
Total liabilities and stockholders' equity	$463,414	$399,890

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts	$543	$623
Preferred stock, par value per share	$0.10	$0.10
Preferred stock, shares authorized	400,000	400,000
Preferred stock, shares issued	'	'
Common stock, par value per share	$0.10	$0.10
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	30,997,686	30,766,730
Treasury stock, shares	2,310,634	2,310,634

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Non- Controlling Interest	Treasury Stock
In Thousands, except Share data
Beginning Balance at Dec. 31, 2012	$225,436	$3,077	$54,323	$174,243	($1,762)	$359	($4,804)
Beginning Balance (in shares) at Dec. 31, 2012	30,766,730	30,766,730	'	'	'	'	2,310,634
Stocks issued under ESPP (in shares)	'	12,263	'	'	'	'	'
Stocks issued under ESPP	378	2	376	'	'	'	'
Cash dividends on common stock	-1,976	'	'	-1,976	'	'	'
Foreign currency translation adjustment, net	407	'	'	'	407	'	'
Stock based compensation	688	'	688	'	'	'	'
Change in fair value of interest rate swaps	178	'	'	'	178	'	'
Stock options exercised and grants of restricted stock units (in shares)	'	144,550	'	'	'	'	'
Stock options exercised and grants of restricted stock units	49	15	34	'	'	'	'
Excess tax benefits from share based payment arrangements	57	'	57	'	'	'	'
Net income (loss)	16,819	'	'	16,915	'	-96	'
Ending Balance at Mar. 31, 2013	242,036	3,094	55,478	189,182	-1,177	263	-4,804
Ending Balance (in shares) at Mar. 31, 2013	'	30,923,543	'	'	'	'	2,310,634
Cash dividends on common stock	-1,413	'	'	-1,413	'	'	'
Foreign currency translation adjustment, net	-476	'	'	'	-476	'	'
Stock based compensation	1,058	'	1,058	'	'	'	'
Change in fair value of interest rate swaps	174	'	'	'	174	'	'
Stock options exercised and grants of restricted stock units (in shares)	'	48,505	'	'	'	'	'
Stock options exercised and grants of restricted stock units	101	5	96	'	'	'	'
Net income (loss)	8,266	'	'	8,386	'	-120	'
Ending Balance at Jun. 30, 2013	249,746	3,099	56,632	196,155	-1,479	143	-4,804
Ending Balance (in shares) at Jun. 30, 2013	'	30,972,048	'	'	'	'	2,310,634
Stocks issued under ESPP (in shares)	'	15,660	'	'	'	'	'
Stocks issued under ESPP	365	1	364	'	'	'	'
Cash dividends on common stock	-1,415	'	'	-1,415	'	'	'
Foreign currency translation adjustment, net	-126	'	'	'	-126	'	'
Stock based compensation	1,149	'	1,149	'	'	'	'
Change in fair value of interest rate swaps	133	'	'	'	133	'	'
Stock options exercised and grants of restricted stock units (in shares)	'	9,978	'	'	'	'	'
Stock options exercised and grants of restricted stock units	36	'	36	'	'	'	'
Non-controlling interest contribution	200	'	'	'	'	200	'
Net income (loss)	8,745	'	'	8,870	'	-125	'
Ending Balance at Sep. 30, 2013	$258,833	$3,100	$58,181	$203,610	($1,472)	$218	($4,804)
Ending Balance (in shares) at Sep. 30, 2013	30,997,686	30,997,686	'	'	'	'	2,310,634

Consolidated_Statement_of_Stoc1

Consolidated Statement of Stockholders' Equity (Parenthetical) (USD $)	3 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013
Cash dividends on common stock, per share	$0.05	$0.05	$0.07

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net income	$33,830	$25,554
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization of fixed and intangible assets	11,183	9,915
Amortization of other long term assets	2,976	2,061
Amortization of discounted liabilities	130	592
Stock-based compensation	2,895	1,856
Tax benefit from exercise of stock options	-57	-493
Loss from equity method investment	386	'
Changes in assets and liabilities associated with operations:	'	'
Increase in net receivables	-34,304	-36,515
Increase in inventories	-39,221	-21,747
Increase in prepaid expenses and other assets	-14,564	-8,862
(Increase) decrease in income tax receivable/payable, net	-520	644
Increase in accounts payable	412	8,743
Decrease in deferred revenue	-20,034	-6,270
Increase in other liabilities	64,088	37,623
Net cash provided by operating activities	7,200	13,101
Cash flows from investing activities:	'	'
Capital expenditures	-12,290	-14,908
Investment	-3,687	'
Net cash used in investing activities	-15,977	-14,908
Cash flows from financing activities:	'	'
Net borrowings under line of credit agreement	38,750	'
Payments on long-term debt	-46,000	-6,000
Payments on other long-term liabilities	-1,415	'
Tax benefit from exercise of stock options	57	493
Decrease in other notes payable	-6,154	-6,460
Payment of cash dividends	-3,390	-1,380
Proceeds from the issuance of common stock (sale of stock under ESPP and exercise of stock options)	929	3,260
Net cash used in financing activities	-17,223	-10,087
Net decrease in cash	-26,000	-11,894
Cash and cash equivalents at beginning of year	38,476	35,085
Effect of exchange rate changes on cash	-151	433
Cash and cash equivalents as of September 30	$12,325	$23,624

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Summary of Significant Accounting Policies	'
	1. The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation, have been included. Operating results for the nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

Property_Plant_and_Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment	'
	2. Property, plant and equipment at September 30, 2013 and December 31, 2012 consists of the following:
		September 30,			December 31,
		2013			2012
	Land	$	2,458		$	2,458
	Buildings and improvements		12,768			12,537
	Machinery and equipment		93,175			89,089
	Office furniture, fixtures and equipment		9,469			8,400
	Automotive equipment		278			312
	Construction in progress		10,301			3,363
			128,449			116,159
	Less accumulated depreciation		(76,807	)		(70,458	)
		$	51,642		$	45,701

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Inventories	'
	3. Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. The components of inventories consist of the following:
		September 30,		December 31,
		2013		2012
	Finished products	$	114,754	$	74,900
	Raw materials		12,418		13,051
		$	127,172	$	87,951

Segment_Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2013
Segment Reporting	'
	4. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information is as follows:
		Three Months Ended				Nine Months Ended
		30-Sep				30-Sep
		2013		2012		2013		2012
	Net sales:
	Insecticides	$	49,539	$	34,603	$	167,624	$	135,869
	Herbicides		28,880		24,813		86,565		58,145
	Other		9,189		19,448		26,108		40,031
			87,608		78,864		280,297		234,045
	Non-crop		9,593		10,972		25,202		27,883
		$	97,201	$	89,836	$	305,499	$	261,928
		Three Months Ended				Nine Months Ended
		30-Sep				30-Sep
		2013		2012		2013		2012
	Net Sales:
	US sales	$	79,425	$	74,036	$	250,367	$	209,371
	International sales		17,776		15,800		55,132		52,557
		$	97,201	$	89,836	$	305,499	$	261,928

Accrued_Program_Costs

Accrued Program Costs	9 Months Ended
	Sep. 30, 2013
Accrued Program Costs	'
	5. Accrued Program Costs—In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, the Company classifies certain payments to its customers as a reduction of sales revenues. The Company describes these payments as “Programs”. Programs are a critical part of doing business in the agricultural chemicals business place. For accounting purposes, programs are recorded as a reduction in gross sales and include market pricing adjustments, volume take up or other key performance indicator driven payments made to distributors, retailers or growers at the end of a growing season. Each quarter management compares each sale transaction with published programs to determine what program liability has been incurred. Once this initial calculation is made for the specific quarter, sales and marketing management along with executive and financial management review the accumulated program balance and make assessments of whether or not customers are tracking in a manner that indicates that they will meet the requirements set out in the terms and conditions attached to each program. If management believes that customers are falling short of their annual goals then periodic adjustments will be made to the accumulated accrual to properly reflect the Company’s best estimate of the liability at the balance sheet date. The majority of adjustments are made at the end of the crop season at which time customer performance can be fully assessed. Programs are paid out predominantly on an annual basis, usually in the final quarter of the financial year or the first quarter of the following year. At September 30, 2013, the balance of accrued program cost is at $95,722 as compared to $32,335 at December 31, 2012.

Cash_Dividends

Cash Dividends	9 Months Ended
	Sep. 30, 2013
Cash Dividends	'
	6. On September 9, 2013, the Board of Directors declared a cash dividend of $0.05 per share. The dividend was distributed on October 18, 2013 to stockholders of record at the close of business on October 4, 2013. Cash dividends paid October 18, 2013 totaled $1,415.
	On June 10, 2013, the Board of Directors declared a cash dividend of $0.05 per share. At that time, the Board of Directors also resolved to change the frequency of making cash dividends from semi-annual to quarterly payments. The first quarterly dividend was distributed on July 19, 2013 to stockholders of record at the close of business on July 5, 2013. Cash dividends paid July 19, 2013 totaled $1,413.
	On March 11, 2013, the Board of Directors declared a cash dividend of $0.07 per share. The dividend was distributed on April 19, 2013 to stockholders of record at the close of business on April 5, 2013. Cash dividends paid April 19, 2013 totaled $1,976.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share	'
	7. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260 Earnings Per Share (“EPS”) requires dual presentation of basic EPS and diluted EPS on the face of all income statements. Basic EPS is computed as net income divided by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects potential dilution that could occur if securities or other contracts, which, for the Company, consists of options to purchase shares of the Company’s common stock, are exercised.
	The components of basic and diluted earnings per share were as follows:
		Three Months Ended				Nine Months Ended
		30-Sep				September 30
		2013		2012		2013		2012
	Numerator:
	Net income attributable to American Vanguard	$	8,870	$	8,076	$	34,171	$	25,554
	Denominator:
	Weighted averages shares outstanding		28,322		27,970		28,295		27,818
	Assumed exercise of stock options and restricted shares-fully diluted		567		908		595		855
			28,889		28,878		28,890		28,673

Indebtedness

Indebtedness	9 Months Ended
	Sep. 30, 2013
Indebtedness	'
	8. Substantially all of the Company’s assets are pledged as collateral with its banks.
	The Company has various loans in place that together constitute the short-term and long-term loan balances shown in the balance sheet at September 30, 2013 and December 31, 2012. These are summarized in the following table:
	Indebtedness	September 30, 2013												December 31, 2012
	$000’s	Long-term				Short-term				Total				Long-term				Short-term			Total
	Term loan	$	—			$	—			$	—			$	36,000			$	10,000		$	46,000
	Working capital revolver		38,750				—				38,750				—				—			—
	Notes payable on product acquisitions and asset purchase		144				71				215				196				6,247			6,443
	Total indebtedness	$	38,894			$	71			$	38,965			$	36,196			$	16,247		$	52,443
	As more fully reported in the Company’s Form 8-K (filed with the SEC on June 20, 2013), on June 17, 2013, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into a Second Amended and Restated Credit Agreement (the “New Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. The new facility also includes both AMVAC C.V. and AMVAC Netherlands BV (both Dutch subsidiaries) as borrowers. The New Credit Agreement supersedes the Amended and Restated Credit Agreement (“First Amendment”) dated as of January 10, 2011 and more fully described in the Company’s Form 8-K filed on January 13, 2011. The New Credit Agreement is a senior secured lending facility with a five year term and consists of a revolving line of credit of $200 million and an accordion feature for up to $100 million. In connection with AMVAC’s entering into the New Credit Agreement, all outstanding indebtedness under the First Amendment was rolled over into the New Credit Agreement, including the conversion of term loans into revolving debt.
	At September 30, 2013, the Company had in place one interest rate swap contract with a notional amount of $38,625 that is accounted for under FASB ASC 815 as a cash flow hedge. The effective portion of the gains or losses on the interest rate swap are reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Losses in other comprehensive income expected to be reclassified to earnings in the coming
	12 months are $596. Amounts recorded in earnings for hedge ineffectiveness for the period ending September 2013 were immaterial.
	The following tables illustrate the impact of derivatives on the Company’s consolidated statement of operations for the three months and nine months ended September 30, 2013.
	The Effect of Derivative Instruments on the Statement of Financial Performance
	For the Period Ended September 30
	For the three months ended September 30
	Derivatives in ASC 815	Amount of Gain or								Location of Gain or		Amount of Gain or (Loss)								Location of Gain or	Amount of Gain or
	Cash Flow	(Loss) Recognized in								(Loss) Reclassified		Reclassified from Accumulated								(Loss) Recognized in	(Loss)
	Hedging Relationships	OCI on Derivative								from Accumulated		OCI into Income (Effective								Income on Derivative	Recognized
		(Effective Portion)								OCI into Income		Portion)								(Ineffective Portion)	in Income on
										(Effective Portion)											Derivative
																					(Ineffective Portion)
		2013				2012						2013				2012					2013			2012
	Interest rate contracts	$	(43	)		$	(137	)		Interest Expense		$	(176	)		$	(178	)		Interest Expense	$	—		$	—
	Total	$	(43	)		$	(137	)				$	(176	)		$	(178	)			$	—		$	—
	Derivatives Not Designated as Hedging Instruments under	Location of Gain or (Loss) Recognized in Income		Amount of
	ASC 815	on		Gain or (Loss)
		Derivative		Recognized in
				Income on
				Derivative
				2013				2012
	Foreign Exchange contracts	Other income/(expense)		$	—			$	115
	Total			$	—			$	115
	For the nine months ended September 30
	Derivatives in ASC 815	Amount of Gain or								Location of Gain or		Amount of Gain or (Loss)								Location of Gain or	Amount of Gain or
	Cash Flow	(Loss) Recognized in								(Loss) Reclassified		Reclassified from Accumulated								(Loss) Recognized in	(Loss)
	Hedging Relationships	OCI on Derivative								from Accumulated		OCI into Income (Effective								Income on Derivative	Recognized
		(Effective Portion)								OCI into Income		Portion)								(Ineffective  Portion)	in Income on
										(Effective Portion)											Derivative
																					(Ineffective Portion)
		2013				2012						2013				2012					2013			2012
	Interest rate contracts	$	(59	)		$	(460	)		Interest Expense		$	(543	)		$	(546	)		Interest Expense	$	(1	)	$	(1	)
	Total	$	(59	)		$	(460	)				$	(543	)		$	(546	)			$	(1	)	$	(1	)
	Derivatives Not Designated as Hedging Instruments	Location of Gain or (Loss) Recognized in Income		Amount of
	under ASC 815	on		Gain or (Loss)
		Derivative		Recognized in
				Income on
				Derivative
				2013				2012
	Foreign Exchange contracts	Other income/(expense)		$	—			$	(77	)
	Total			$	—			$	(77	)
	The Company has three key covenants to its senior, secured credit facility with its banking syndicate. The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio, (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. As of September 30, 2013 the Company met all covenants in that credit facility.
	At September 30, 2013, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $161,250 under the credit facility agreement.

Reclassification

Reclassification	9 Months Ended
	Sep. 30, 2013
Reclassification	'
	9. Reclassification—certain items may have been reclassified (if appropriate), in the prior period consolidated financial statements to conform to the most recent financial statements presented.

Comprehensive_Income

Comprehensive Income	9 Months Ended
	Sep. 30, 2013
Comprehensive Income	'
	10. Total comprehensive income includes, in addition to net income, changes in equity that are excluded from the consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the consolidated balance sheets. For the three month and nine month periods ended September 30, 2013, total comprehensive income consisted of net income attributable to American Vanguard, the change in fair value of interest rate swaps and foreign currency translation adjustments.

Stock_Based_Compensation_Expen

Stock Based Compensation Expense	9 Months Ended
	Sep. 30, 2013
Stock Based Compensation Expense	'
	11. Stock Based Compensation Expense—The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, “Share-Based Payment,” which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including shares of common stock granted for services, employee stock options, and employee stock purchases related to the Employee Stock Purchase Plan (“employee stock purchases”) based on estimated fair values.
	Stock Options—During the nine months ended September 30, 2013, the Company did not grant any employees options to acquire shares of common stock.
	Option activity within each plan is as follows:
		Incentive			Weighted Average		Exercisable
		Stock Option			Price Per Share		Weighted
		Plans					Average
							Price
							Per Share
	Balance outstanding, January 1, 2013		705,345		$	7.7	$	7.95
	Options granted		—			—
	Options exercised, $7.50		(6,666	)		7.5
	Options expired or forfeited		(6,667	)		7.5
	Balance outstanding, March 31, 2013		692,012		$	7.71	$	7.96
	Options granted		—			—
	Options exercised, $7.50		(13,333	)		7.5
	Options expired or forfeited		—			—
	Balance outstanding, June 30, 2013		678,679		$	7.71	$	8.07
	Options granted		—			—
	Options exercised, $7.50		(6,666	)		7.5
	Options expired or forfeited		(4,000	)		7.5
	Balance outstanding, September 30, 2013		668,013		$	7.72	$	8.2
	Information relating to stock options at September 30, 2013 summarized by exercise price is as follows:
		Outstanding Weighted Average							Exercisable Weighted
									Average
	Exercise Price Per Share	Shares			Remaining		Exercise		Shares		Exercise
					Life		Price				Price
					(Months)
	Incentive Stock Option Plan:
	$7.50		641,334			83	$	7.5		139,334	$	7.5
	$11.32—$14.75		26,679			83	$	12.9		20,012	$	13.1
			668,013				$	7.72		159,346	$	8.2
	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of September 30, 2013 was as follows:
		Number			Weighted		Weighted		Intrinsic
		of			Average		Average		Value
		Shares			Exercise		Remaining		(thousands)
					Price		Contractual
							Life
							(Months)
	As of September 30, 2013:
	Incentive Stock Option Plans:
	Outstanding		668,013		$	7.72		83	$	12,829
	Expected to Vest		666,233		$	7.72		83	$	12,795
	Exercisable		159,346		$	8.2		72	$	2,982
	During the three months ended September 30, 2013 and 2012, the Company recognized stock-based compensation expense, excluding expense related to modifications, related to stock options of $201 and $236, respectively.
	During the nine months ended September 30, 2013 and 2012, the Company recognized stock-based compensation expense, excluding expense related to modifications, related to stock options of $624 and $668, respectively.
	As of September 30, 2013, the Company had approximately $186 of unamortized stock-based compensation expenses related to unvested stock options outstanding. This amount will be recognized over the weighted-average period of 0.3 years. This projected expense will change if any stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.
	Restricted Shares—A status summary of non-vested shares as of and for the nine months ended September 30, 2013 is presented below:
		Number of			Weighted
		Shares			Average
					Grant-Date
					Fair Value
	Nonvested shares at January 1, 2013		245,817		$	20.23
	Granted		145,884		$	31.27
	Vested		—		$	—
	Forfeited		(8,000	)	$	22.17
	Nonvested shares at March 31, 2013		383,701		$	24.39
	Granted		8,230			30.19
	Vested		(8,230	)		30.37
	Forfeited		—		$	—
	Nonvested shares at June 30, 2013		383,701		$	24.87
	Granted		4,500			24.27
	Vested		(5,000	)		8.32
	Forfeited		—		$	—
Nonvested shares at September 30, 2013		383,201		$	24.6
Restricted stock grants—During the nine months ended September 30, 2013, the Company granted a total of 158,614 shares of common stock. Of these, 8,230 shares vested immediately, 1,500 shares will cliff vest after four hundred fifty days and the balance of 148,884 shares will cliff vest after three years of service. The shares granted in 2013 were fair valued at $31.06 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period. During the nine months ended September 30, 2013, there were 13,230 restricted shares that vested, which had an average grant-date value of $22.04 per share and an average vest-date value of $24.01 per share. During the nine months ended September 30, 2013, there were 8,000 restricted shares that were forfeited, which had an average grant date value of $22.17 per share.
During the nine months ended September 30, 2012, the Company granted a total of 247,536 shares of common stock. Of these, 13,352 shares vested immediately, 7,000 shares vested after ninety days and the balance of 227,184 shares will cliff vest after three years of service. The shares granted in 2012 were fair valued at $21.24 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company recognizes as expense the value of restricted shares over the required service period. During the nine months ended September 30, 2012, there were 99,992 restricted shares that vested, which had an average grant-date value of $14.13 per share and an average vest-date value of $19.29 per share. During the nine months ended September 30, 2012, there were 1,367 restricted shares that were forfeited, which had an average grant date value of $20.47 per share.
During the three months ended September 30, 2013 and 2012, the Company recognized stock-based compensation expense related to restricted shares of $856 and $589, respectively.
During the nine months ended September 30, 2013 and 2012, the Company recognized stock-based compensation expense related to restricted shares of $2,153 and $1,188, respectively.
As of September 30, 2013, the Company had approximately $6,370 of unamortized stock-based compensation expenses related to unvested restricted shares. This amount will be recognized over the weighted-average period of 2.1 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.
Performance Based Shares—A status summary of non-vested performance based shares as of and for the nine months ended September 30, 2013 is presented below:
	Number			Weighted
	of			Average
	Shares			Grant-
				Date
				Fair Value
Nonvested shares at March 31, 2013		—		$	—
Granted		24,637		$	30.13
Vested		—		$	—
Forfeited		—		$	—
Nonvested shares at June 30, 2013		24,637		$	30.13
Granted		—		$	—
Vested		—		$	—
Forfeited		—		$	—
Nonvested shares at September 30, 2013		24,637		$	30.13
Performance Based Shares — During the nine months ended September 30, 2013, the Company granted a total of 24,637 performance based shares that will cliff vest after three years of service. 80% of this performance based shares are based upon net income and net sales for the period commencing April 1, 2013 and ending December 31, 2015; the remaining 20% of performance based shares are based upon AVD stock price appreciation over the course of the period commencing June 6, 2013 and ending on December 31, 2015. Both parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for meeting less than the targeted performance and to increase to a maximum of 200% for meeting in excess of the targeted performance.
The performance based shares related to net income and net sales were average fair valued at $30.13 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The performance based shares related to AVD stock price were average fair valued at $15.31 per share. The fair value was determined by using the Monte Carlo valuation method. The Company recognizes as expense the value of these shares over the required service period of three years.
During the three months ended September 30, 2013, the Company recognized stock-based compensation expense related to performance based shares of $92. There were no performance based shares issued by the Company prior to those issued during the quarter ended June 30, 2013.
During the nine months ended September 30, 2013, the Company recognized stock-based compensation expense related to performance based shares of $118. There were no performance based shares issued by the Company prior to those issued during the quarter ended June 30, 2013.
As of September 30, 2013, the Company had approximately $623 of unamortized stock-based compensation expenses related to unvested performance based shares. This amount will be recognized over the weighted-average period of 2.7 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

Legal_Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2013
Legal Proceedings	'
	12. Legal Proceedings—Summarized below are litigation matters in which there has been material activity or developments during the three month period ended September 30, 2013.
	A. DBCP Cases
	A number of suits have been filed against AMVAC, alleging injury from exposure to the agricultural chemical 1, 2-dibromo-3-chloropropane (“DBCP®”). DBCP was manufactured by several chemical companies, including Dow Chemical Company, Shell Oil Company and AMVAC, and was approved by the United States Environmental Protection Agency (“USEPA”) to control nematodes. DBCP was also applied on banana farms in Latin America. The USEPA suspended registrations of DBCP in October 1979, except for use on pineapples in Hawaii. The USEPA suspension was partially based on 1977 studies by other manufacturers that indicated a possible link between male fertility and exposure to DBCP among their factory production workers involved with producing the product. There are approximately 100 lawsuits, foreign and domestic, filed by former banana workers in which AMVAC has been named as a party. Fifteen of these suits have been filed in the United States (with prayers for unspecified damages) and the remainder have been filed in Nicaragua. All of these actions are in various stages and allege injury from exposure to DBCP, including claims for sterility. Following is a summary of material developments in these matters since the commencement of this reporting period. For the sake of brevity, we refer to cases by the names set forth in the Company’s Form 10-K for the period ended December 31, 2012, which sets forth the procedural history of these matters in greater detail.
	Delaware and Louisiana Matters
	On September 19, 2013, in Marquinez, (U.S. District Court for the District of Delaware, Case No. 12-695-RGA involving claims for injury to 22 banana plantation workers allegedly caused by exposure to DBCP), the court granted in part, and denied in part, a motion to dismiss filed by Dole and, in the process, dismissed 14 of the 22 plaintiffs on the ground that they had been named as plaintiffs in a prior action filed by the Hendler law firm in Louisiana. As for the remaining eight plaintiffs, the court found that there was a question as to whether they were parties to the Louisiana case(s). On the question of cross-jurisdictional tolling (which had been raised in the motion), the court invited Dole to renew its motion to dismiss pending a decision from the Fifth Circuit Court of Appeals in the Hendler-Louisiana cases. As indicated below, the Fifth Circuit did render a decision on the appeal of the Hendler-Louisiana cases, and Dole has renewed its motion to dismiss Marquinez. With respect to the Marquinez matter, the company has filed an answer to the complaint, no discovery has commenced in this matter, and it is too early to predict whether a loss is either probable or reasonably estimable; accordingly, the company has not set up a loss contingency on either of these matters.
	Also on September 19, 2013, the Fifth Circuit Court of Appeal affirmed the order of the U.S. District Court for the Eastern District of Louisiana granting summary judgment on the claims of 258 of the plaintiffs named in the Hendler-Louisiana cases. The appellate court found no basis for reversing the lower court dismissal which had been effected on the ground that claimants had not brought their actions within the applicable statute of limitations period.
	In a related matter, on October 16, 2013, plaintiffs filed a notice of appeal with the U.S. Court of Appeals for the Third Circuit from the order issued by the U.S. District Court in the Hendler-Delaware cases, in which the court dismissed the claims of 235 plaintiffs on the ground that the actions were already pending in Louisiana (as the Hendler-Louisiana cases) and, as such, were barred from adjudication before another court under the “first-to-file” rule. In effect, plaintiffs, whose claims were dismissed by the federal court in Louisiana (and which appeal was affirmed on appeal as per the previous paragraph) are attempting to keep those claims alive before the Delaware federal courts. The Company does not believe that there is any merit in the appeal and plans to oppose it vigorously. Accordingly, the Company has not set up a loss contingency on this matter.
	B. Other Matters
	Brazilian Citation. On or about October 5, 2009, IBAMA (the Brazilian equivalent of the USEPA) served AMVAC Brazil (“AMVAC B”) with a Notice of Violation alleging that two lots of Granutox 150 (formulated product having phorate as the active ingredient) stored at BASF S.A. (AMVAC’s exclusive distributor in Brazil) and FMC Quimica do Brasil Ltda. (which formulates end-use product in that country) were not in compliance with the end-use registration on file with IBAMA. Specifically, IBAMA alleged that the color of the lots (gray) was inconsistent with the description in IBAMA’s files (pink). IBAMA also indicated an intention to assess a fine of approximately $200 against AMVAC B. The Company has challenged the citation, for among other reasons, on the ground that the change in color has to do with the removal of a coloring component and that such removal poses no environmental or toxicity risk. In March 2011, IBAMA denied AMVAC B’s first appeal. The Company believes, however, that the agency is statutorily prevented from levying a fine of this magnitude for an infraction of this nature. Thus, the Company has filed another appeal on these grounds and expects to hear a response during 2013. At this stage, the Company believes that a loss of between $200 and $300 is probable and has set up a loss contingency in the amount of $200.

Recently_Issued_Accounting_Gui

Recently Issued Accounting Guidance	9 Months Ended
	Sep. 30, 2013
Recently Issued Accounting Guidance	'
	13. Recently Issued Accounting Guidance— In February 2013, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, establishes new requirements for disclosing reclassifications of items out of accumulated other comprehensive income (OCI). Specifically, (1) disclosure is required of the changes in components of accumulated OCI, (2) disclosure is required of the effects on individual line items in net income for each item of accumulated OCI that is reclassified in its entirety to net income, and (3) cross references are required to other disclosures that provide additional details for OCI items that are not reclassified in their entirety to net income. The requirements of ASU 2013-02 apply to all entities (i.e., both public and nonpublic) that report items of OCI in any period presented. ASU 2013-02 is effective prospectively for reporting periods beginning after December 15, 2012. The Company adopted this standard effective January 1, 2013.
	In October 2012, FASB issued ASU No. 2012-04, Technical Corrections and Improvements. This update primarily makes amendments to various Codifications to (1) conform the format and writing style of certain guidance carried forward without modification from pre-Codification pronouncements, (2) to correct references and provide clarification through updated language, and (3) to relocate guidance within the Codification to a more appropriate location. In addition, ASU No. 2012-4 conforms the use of the term fair value throughout the Codification to reflect fully the measurement and disclosure requirements of FASB ASC Topic 820, Fair Value Measurement and Disclosures (e.g. to replace the terms “market value” and “mark-to-market” with “fair value” and “subsequently measure at fair value,” respectively). The majority of the amendments do not change the accounting practice. However, where applicable, the Company has applied the updates.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2013
Fair Value of Financial Instruments	'
	14. Fair Value of Financial Instruments—The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company’s long-term debt and note payable to bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company’s long-term debt and note payable to bank.
	The Company’s cash flow hedge related to a variable debt instrument and outstanding foreign currency derivatives used to hedge foreign currency balances are measured at fair value on a recurring basis, and the balances as of September 30, 2013 and December 31, 2012 (which are included in other assets, net and accrued and other liabilities in the consolidated balance sheets) were as follows:
			Fair Value Measurements
			Using Input Type
			Level 1		Level 2		Level 3
	As of September 30, 2013:
	Liability:
	Foreign currency derivative financial instrument		$	—	$	—	$	—
	Interest rate derivative financial instruments (1)		$	—	$	716	$	—
	As of December 31, 2012:
	Liability:
	Foreign currency derivative financial instrument		$	—	$	160	$	—
	Interest rate derivative financial instruments (1)		$	—	$	1,201	$	—
	-1	Includes accrued interest expense
	The valuation techniques used to measure the fair value of the derivative financial instruments above, in which the counterparties have high credit ratings, were derived from pricing models, such as discounted cash flow techniques, with all significant inputs derived from or corroborated by observable market data. The Company’s discounted cash flow techniques use observable market inputs, such as LIBOR-based yield curves and foreign currency forward rates.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income	'
	15. Accumulated Other Comprehensive Income—
	The following table lists the beginning balance, annual activity and ending balance of each component of accumulated other comprehensive income:
		Interest			FX			Total
		Rate			Translation
		Swap
	Balance, December 31, 2012	$	(728	)	$	(1,034	)	$	(1,762	)
	Current period, other comprehensive income		178			407			585
	Balance, March 31, 2013	$	(550	)	$	(627	)	$	(1,177	)
	Current period, other comprehensive income		174			(476	)		(302	)
	Balance, June 30, 2013	$	(376	)	$	(1,103	)	$	(1,479	)
	Current period, other comprehensive income		133			(126	)		7
	Balance, September 30, 2013	$	(243	)	$	(1,229	)	$	(1,472	)

Equity_Investment

Equity Investment	9 Months Ended
	Sep. 30, 2013
Equity Investment	'
	16. In March 2013, the Company made a $3,687 equity investment in TyraTech Inc. (“TyraTech”), a natural life science company that aims to utilize its proprietary technology to develop solutions to address the unmet and increasing global demand for effective, safe, insect and parasite technologies for human and animal health. As of September 30, 2013, the Company’s ownership position in TyraTech was approximately 29.27%. The Company utilizes the equity method of accounting with respect to this investment. As a result, our net income includes earnings (losses) from equity method investments, which represents our proportionate share of TyraTech’s net earnings (losses) for the period from the time of the investment to the end of the accounting period. The earnings or losses based on unaudited published financial statements from TyraTech are reflected in our financial statements during the quarter immediately following the period in which the results are published by TyraTech.
	The Company’s investment in TyraTech is carried at the equity method valuation and is included in other assets on the balance sheet. At September 30, 2013, the carrying value of the Company’s investment in TyraTech was $3,301 and the quoted market value was $4,288.

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Summary of Property, Plant and Equipment	'
	2. Property, plant and equipment at September 30, 2013 and December 31, 2012 consists of the following:
		September 30,			December 31,
		2013			2012
	Land	$	2,458		$	2,458
	Buildings and improvements		12,768			12,537
	Machinery and equipment		93,175			89,089
	Office furniture, fixtures and equipment		9,469			8,400
	Automotive equipment		278			312
	Construction in progress		10,301			3,363
			128,449			116,159
	Less accumulated depreciation		(76,807	)		(70,458	)
		$	51,642		$	45,701

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Components of Inventories	'
	The components of inventories consist of the following:
		September 30,		December 31,
		2013		2012
	Finished products	$	114,754	$	74,900
	Raw materials		12,418		13,051
		$	127,172	$	87,951

Segment_Reporting_Tables

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2013
Summary of Business Sales Segmentation as per Product	'
	Selective enterprise information is as follows:
		Three Months Ended				Nine Months Ended
		30-Sep				30-Sep
		2013		2012		2013		2012
	Net sales:
	Insecticides	$	49,539	$	34,603	$	167,624	$	135,869
	Herbicides		28,880		24,813		86,565		58,145
	Other		9,189		19,448		26,108		40,031
			87,608		78,864		280,297		234,045
	Non-crop		9,593		10,972		25,202		27,883
		$	97,201	$	89,836	$	305,499	$	261,928
Summary of Business Sales Segmentation as per Location	'
		Three Months Ended				Nine Months Ended
		30-Sep				30-Sep
		2013		2012		2013		2012
	Net Sales:
	US sales	$	79,425	$	74,036	$	250,367	$	209,371
	International sales		17,776		15,800		55,132		52,557
		$	97,201	$	89,836	$	305,499	$	261,928

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Components of Basic and Diluted Earnings Per Share	'
	The components of basic and diluted earnings per share were as follows:
		Three Months Ended				Nine Months Ended
		30-Sep				September 30
		2013		2012		2013		2012
	Numerator:
	Net income attributable to American Vanguard	$	8,870	$	8,076	$	34,171	$	25,554
	Denominator:
	Weighted averages shares outstanding		28,322		27,970		28,295		27,818
	Assumed exercise of stock options and restricted shares-fully diluted		567		908		595		855
			28,889		28,878		28,890		28,673

Indebtedness_Tables

Indebtedness (Tables)	9 Months Ended
	Sep. 30, 2013
Summary of Short-Term and Long-Term Loan Balances in Balance Sheet	'
	The Company has various loans in place that together constitute the short-term and long-term loan balances shown in the balance sheet at September 30, 2013 and December 31, 2012. These are summarized in the following table:
	Indebtedness	September 30, 2013												December 31, 2012
	$000’s	Long-term				Short-term				Total				Long-term				Short-term			Total
	Term loan	$	—			$	—			$	—			$	36,000			$	10,000		$	46,000
	Working capital revolver		38,750				—				38,750				—				—			—
	Notes payable on product acquisitions and asset purchase		144				71				215				196				6,247			6,443
	Total indebtedness	$	38,894			$	71			$	38,965			$	36,196			$	16,247		$	52,443
Summary of Effect of Derivative Instruments on Statement of Financial Performance	'
	The following tables illustrate the impact of derivatives on the Company’s consolidated statement of operations for the three months and nine months ended September 30, 2013.
	The Effect of Derivative Instruments on the Statement of Financial Performance
	For the Period Ended September 30
	For the three months ended September 30
	Derivatives in ASC 815	Amount of Gain or								Location of Gain or		Amount of Gain or (Loss)								Location of Gain or	Amount of Gain or
	Cash Flow	(Loss) Recognized in								(Loss) Reclassified		Reclassified from Accumulated								(Loss) Recognized in	(Loss)
	Hedging Relationships	OCI on Derivative								from Accumulated		OCI into Income (Effective								Income on Derivative	Recognized
		(Effective Portion)								OCI into Income		Portion)								(Ineffective Portion)	in Income on
										(Effective Portion)											Derivative
																					(Ineffective Portion)
		2013				2012						2013				2012					2013			2012
	Interest rate contracts	$	(43	)		$	(137	)		Interest Expense		$	(176	)		$	(178	)		Interest Expense	$	—		$	—
	Total	$	(43	)		$	(137	)				$	(176	)		$	(178	)			$	—		$	—
	Derivatives Not Designated as Hedging Instruments under	Location of Gain or (Loss) Recognized in Income		Amount of
	ASC 815	on		Gain or (Loss)
		Derivative		Recognized in
				Income on
				Derivative
				2013				2012
	Foreign Exchange contracts	Other income/(expense)		$	—			$	115
	Total			$	—			$	115
	For the nine months ended September 30
	Derivatives in ASC 815	Amount of Gain or								Location of Gain or		Amount of Gain or (Loss)								Location of Gain or	Amount of Gain or
	Cash Flow	(Loss) Recognized in								(Loss) Reclassified		Reclassified from Accumulated								(Loss) Recognized in	(Loss)
	Hedging Relationships	OCI on Derivative								from Accumulated		OCI into Income (Effective								Income on Derivative	Recognized
		(Effective Portion)								OCI into Income		Portion)								(Ineffective  Portion)	in Income on
										(Effective Portion)											Derivative
																					(Ineffective Portion)
		2013				2012						2013				2012					2013			2012
	Interest rate contracts	$	(59	)		$	(460	)		Interest Expense		$	(543	)		$	(546	)		Interest Expense	$	(1	)	$	(1	)
	Total	$	(59	)		$	(460	)				$	(543	)		$	(546	)			$	(1	)	$	(1	)
	Derivatives Not Designated as Hedging Instruments	Location of Gain or (Loss) Recognized in Income		Amount of
	under ASC 815	on		Gain or (Loss)
		Derivative		Recognized in
				Income on
				Derivative
				2013				2012
	Foreign Exchange contracts	Other income/(expense)		$	—			$	(77	)
	Total			$	—			$	(77	)

Stock_Based_Compensation_Expen1

Stock Based Compensation Expense (Tables)	9 Months Ended
	Sep. 30, 2013
Summary of Option Activity	'
	Option activity within each plan is as follows:
		Incentive			Weighted Average		Exercisable
		Stock Option			Price Per Share		Weighted
		Plans					Average
							Price
							Per Share
	Balance outstanding, January 1, 2013		705,345		$	7.7	$	7.95
	Options granted		—			—
	Options exercised, $7.50		(6,666	)		7.5
	Options expired or forfeited		(6,667	)		7.5
	Balance outstanding, March 31, 2013		692,012		$	7.71	$	7.96
	Options granted		—			—
	Options exercised, $7.50		(13,333	)		7.5
	Options expired or forfeited		—			—
	Balance outstanding, June 30, 2013		678,679		$	7.71	$	8.07
	Options granted		—			—
	Options exercised, $7.50		(6,666	)		7.5
	Options expired or forfeited		(4,000	)		7.5
	Balance outstanding, September 30, 2013		668,013		$	7.72	$	8.2
Summary of Stock Options Summarized by Exercise Price	'
	Information relating to stock options at September 30, 2013 summarized by exercise price is as follows:
		Outstanding Weighted Average							Exercisable Weighted
									Average
	Exercise Price Per Share	Shares			Remaining		Exercise		Shares		Exercise
					Life		Price				Price
					(Months)
	Incentive Stock Option Plan:
	$7.50		641,334			83	$	7.5		139,334	$	7.5
	$11.32—$14.75		26,679			83	$	12.9		20,012	$	13.1
			668,013				$	7.72		159,346	$	8.2
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	'
	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of September 30, 2013 was as follows:
		Number			Weighted		Weighted		Intrinsic
		of			Average		Average		Value
		Shares			Exercise		Remaining		(thousands)
					Price		Contractual
							Life
							(Months)
	As of September 30, 2013:
	Incentive Stock Option Plans:
	Outstanding		668,013		$	7.72		83	$	12,829
	Expected to Vest		666,233		$	7.72		83	$	12,795
	Exercisable		159,346		$	8.2		72	$	2,982
Summary of Non-Vested Shares	'
	Restricted Shares—A status summary of non-vested shares as of and for the nine months ended September 30, 2013 is presented below:
		Number of			Weighted
		Shares			Average
					Grant-Date
					Fair Value
	Nonvested shares at January 1, 2013		245,817		$	20.23
	Granted		145,884		$	31.27
	Vested		—		$	—
	Forfeited		(8,000	)	$	22.17
	Nonvested shares at March 31, 2013		383,701		$	24.39
	Granted		8,230			30.19
	Vested		(8,230	)		30.37
	Forfeited		—		$	—
	Nonvested shares at June 30, 2013		383,701		$	24.87
	Granted		4,500			24.27
	Vested		(5,000	)		8.32
	Forfeited		—		$	—
	Nonvested shares at September 30, 2013		383,201		$	24.6
Performance Shares	'
Summary of Non-Vested Shares	'
	Performance Based Shares—A status summary of non-vested performance based shares as of and for the nine months ended September 30, 2013 is presented below:
		Number			Weighted
		of			Average
		Shares			Grant-
					Date
					Fair Value
	Nonvested shares at March 31, 2013		—		$	—
	Granted		24,637		$	30.13
	Vested		—		$	—
	Forfeited		—		$	—
	Nonvested shares at June 30, 2013		24,637		$	30.13
	Granted		—		$	—
	Vested		—		$	—
	Forfeited		—		$	—
	Nonvested shares at September 30, 2013		24,637		$	30.13

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2013
Cash Flow Hedge Related to Variable Debt Instrument and Outstanding Foreign Currency Derivatives to Hedge Foreign Currency Balances Measured at Fair Value on Recurring Basis, and Balances	'
	The Company’s cash flow hedge related to a variable debt instrument and outstanding foreign currency derivatives used to hedge foreign currency balances are measured at fair value on a recurring basis, and the balances as of September 30, 2013 and December 31, 2012 (which are included in other assets, net and accrued and other liabilities in the consolidated balance sheets) were as follows:
			Fair Value Measurements
			Using Input Type
			Level 1		Level 2		Level 3
	As of September 30, 2013:
	Liability:
	Foreign currency derivative financial instrument		$	—	$	—	$	—
	Interest rate derivative financial instruments (1)		$	—	$	716	$	—
	As of December 31, 2012:
	Liability:
	Foreign currency derivative financial instrument		$	—	$	160	$	—
	Interest rate derivative financial instruments (1)		$	—	$	1,201	$	—
	-1	Includes accrued interest expense

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2013
Beginning Balance, Annual Activity and Ending Balance of each Component of Accumulated Other Comprehensive Income	'
	The following table lists the beginning balance, annual activity and ending balance of each component of accumulated other comprehensive income:
		Interest			FX			Total
		Rate			Translation
		Swap
	Balance, December 31, 2012	$	(728	)	$	(1,034	)	$	(1,762	)
	Current period, other comprehensive income		178			407			585
	Balance, March 31, 2013	$	(550	)	$	(627	)	$	(1,177	)
	Current period, other comprehensive income		174			(476	)		(302	)
	Balance, June 30, 2013	$	(376	)	$	(1,103	)	$	(1,479	)
	Current period, other comprehensive income		133			(126	)		7
	Balance, September 30, 2013	$	(243	)	$	(1,229	)	$	(1,472	)

Summary_of_Property_Plant_and_

Summary of Property, Plant and Equipment (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	$128,449	$116,159
Less accumulated depreciation	-76,807	-70,458
Total Property, plant and equipment	51,642	45,701
Land	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	2,458	2,458
Buildings and improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	12,768	12,537
Machinery and equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	93,175	89,089
Office furniture, fixtures and equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	9,469	8,400
Automotive equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	278	312
Construction in progress	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	$10,301	$3,363

Components_of_Inventories_Deta

Components of Inventories (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory [Line Items]	'	'
Finished products	$114,754	$74,900
Raw materials	12,418	13,051
Total Inventories	$127,172	$87,951

Summary_of_Business_Sales_Segm

Summary of Business Sales Segmentation as per Product (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net Sales:	'	'	'	'
Total Crop	$87,608	$78,864	$280,297	$234,045
Non-crop	9,593	10,972	25,202	27,883
Total Sales	97,201	89,836	305,499	261,928
Insecticides	'	'	'	'
Net Sales:	'	'	'	'
Total Crop	49,539	34,603	167,624	135,869
Herbicides	'	'	'	'
Net Sales:	'	'	'	'
Total Crop	28,880	24,813	86,565	58,145
Other	'	'	'	'
Net Sales:	'	'	'	'
Total Crop	$9,189	$19,448	$26,108	$40,031

Summary_of_Business_Sales_Segm1

Summary of Business Sales Segmentation as per Location (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net Sales:	'	'	'	'
Total Sales	$97,201	$89,836	$305,499	$261,928
US	'	'	'	'
Net Sales:	'	'	'	'
Total Sales	79,425	74,036	250,367	209,371
International	'	'	'	'
Net Sales:	'	'	'	'
Total Sales	$17,776	$15,800	$55,132	$52,557

Accrued_Program_Costs_Addition

Accrued Program Costs - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Liabilities [Line Items]	'	'
Accrued program costs	$95,722	$32,335

Cash_Dividends_Additional_Info

Cash Dividends - Additional Information (Detail) (USD $)	1 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 09, 2013	Mar. 11, 2013	Jul. 19, 2013	Jun. 10, 2013	Apr. 19, 2013	Oct. 18, 2013
						Subsequent Event
Dividends [Line Items]	'	'	'	'	'	'
Cash dividend declared	$0.05	$0.07	'	$0.05	'	'
Dividend distributed date	18-Oct-13	19-Apr-13	'	19-Jul-13	'	'
Cash dividend record date	4-Oct-13	5-Apr-13	'	5-Jul-13	'	'
Cash dividends paid	'	'	$1,413	'	$1,976	$1,415

Components_of_Basic_and_Dilute

Components of Basic and Diluted Earnings Per Share (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator:	'	'	'	'
Net income attributable to American Vanguard	$8,870	$8,076	$34,171	$25,554
Denominator:	'	'	'	'
Weighted averages shares outstanding	28,322	27,970	28,295	27,818
Weighted average shares outstanding-assuming dilution	28,889	28,878	28,890	28,673
Stock Options	'	'	'	'
Denominator:	'	'	'	'
Assumed exercise of stock options and restricted shares-fully diluted	567	908	595	855

Summary_of_Different_Loans_in_

Summary of Different Loans in Place Constitute Short-Term and Long-Term Loan Balances Together (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Extinguishment of Debt [Line Items]	'	'
Long Term debt	$38,894	$36,196
Short-term	71	16,247
Total indebtedness	38,965	52,443
Term Loan	'	'
Extinguishment of Debt [Line Items]	'	'
Long Term debt	'	36,000
Short-term	'	10,000
Total indebtedness	'	46,000
Working capital revolver	'	'
Extinguishment of Debt [Line Items]	'	'
Long Term debt	38,750	'
Total indebtedness	38,750	'
Notes payable on product acquisitions and asset purchase	'	'
Extinguishment of Debt [Line Items]	'	'
Long Term debt	144	196
Short-term	71	6,247
Total indebtedness	$215	$6,443

Indebtedness_Additional_Inform

Indebtedness - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
	Contract
Debt [Line Items]	'
Number of Interest rate swap contract outstanding	1
Losses in other comprehensive income expected to be reclassified to earnings	($596,000)
Duration of losses in other comprehensive income expected to be reclassified to earnings	'12 months
Revolving Credit Facility	'
Debt [Line Items]	'
Senior secured credit facility	200,000,000
Senior secured credit facility term	'5 years
Revolving Credit Facility | Accordion Feature	'
Debt [Line Items]	'
Senior secured credit facility	100,000,000
Maximum	'
Debt [Line Items]	'
Capacity to increase borrowings under credit agreement	161,250,000
Cash Flow Hedging | Interest Rate Swap	'
Debt [Line Items]	'
Notional amount of interest rate swap	$38,625,000

Summary_of_Effect_of_Derivativ

Summary of Effect of Derivative Instruments on Statement of Financial Performance (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Not Designated as Hedging Instrument	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Amount of Gain or (Loss) Recognized in Income on Derivative	'	$115	'	($77)
Cash Flow Hedging	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	-43	-137	-59	-460
Amount of Gain or (Loss) Reclassified from Accumulated OCI in to Income (Effective Portion)	-176	-178	-543	-546
Amount of Gain or (Loss) Recognized in Income on derivative (Ineffective Portion)	'	'	-1	-1
Foreign Exchange Contract | Other income/(expense) | Not Designated as Hedging Instrument	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Amount of Gain or (Loss) Recognized in Income on Derivative	'	115	'	-77
Interest Rate Contract | Cash Flow Hedging	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	-43	-137	-59	-460
Interest Rate Contract | Interest Expense | Cash Flow Hedging	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Amount of Gain or (Loss) Reclassified from Accumulated OCI in to Income (Effective Portion)	-176	-178	-543	-546
Amount of Gain or (Loss) Recognized in Income on derivative (Ineffective Portion)	'	'	($1)	($1)

Summary_of_Option_Activity_Det

Summary of Option Activity (Detail) (USD $)	3 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Options exercised, Lower Range	$7.50	$7.50	$7.50
Incentive Stock Option Plans, Beginning balance	678,679	692,012	705,345
Incentive Stock Option Plans, Options granted	'	'	'
Incentive Stock Option Plans, Option exercised	-6,666	-13,333	-6,666
Incentive Stock Option Plans, Options expired or forfeited	-4,000	'	-6,667
Incentive Stock Option Plans, Ending balance	668,013	678,679	692,012
Weighted Average Price Per Share, Beginning balance	$7.71	$7.71	$7.70
Weighted Average Price Per Share, Option granted	'	'	'
Weighted Average Price Per Share, Option exercised	$7.50	$7.50	$7.50
Weighted Average Price Per Share, Options forfeited	$7.50	'	$7.50
Weighted Average Price Per Share, Ending balance	$7.72	$7.71	$7.71
Exercisable Weighted Average Price Per Share, Beginning balance	$8.07	$7.96	$7.95
Exercisable Weighted Average Price Per Share, Ending balance	$8.20	$8.07	$7.96

Summary_of_Stock_Options_Summa

Summary of Stock Options Summarized by Exercise Price (Detail) (USD $)	3 Months Ended				9 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
					Incentive Stock Option Plan	Incentive Stock Option Plan	Incentive Stock Option Plan
						Range One	Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Options exercised, Lower Range	$7.50	$7.50	$7.50	'	'	$7.50	$11.32
Options exercised, Upper Range	'	'	'	'	'	'	$14.75
Outstanding Weighted Average, Shares	'	'	'	'	668,013	641,334	26,679
Outstanding Weighted Average, Remaining Life (Months)	'	'	'	'	'83 months	'83 months	'83 months
Outstanding Weighted Average, Exercise Price	$7.72	$7.71	$7.71	$7.70	$7.72	$7.50	$12.90
Exercisable Weighted Average, Shares	'	'	'	'	159,346	139,334	20,012
Exercisable Weighted Average, Exercise Price	$8.20	$8.07	$7.96	$7.95	$8.20	$7.50	$13.10

Weighted_Average_Exercise_Pric

Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) (USD $)	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2013
In Thousands, except Share data, unless otherwise specified					Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Number of Shares, Outstanding	'	'	'	'	668,013
Number of Shares, Expected to Vest	'	'	'	'	666,233
Number of Shares, Exercisable	'	'	'	'	159,346
Weighted Average Exercise Price, Outstanding	$7.72	$7.71	$7.71	$7.70	$7.72
Weighted Average Exercise Price, Expected to Vest	'	'	'	'	$7.72
Weighted Average Exercisable, Exercise Price	$8.20	$8.07	$7.96	$7.95	$8.20
Weighted Average Remaining Life, Outstanding	'	'	'	'	'83 months
Weighted Average Remaining Contractual Life, Expected to Vest	'	'	'	'	'83 months
Weighted Average Remaining Contractual Life, Exercisable	'	'	'	'	'72 months
Intrinsic Value, Outstanding	'	'	'	'	$12,829
Intrinsic Value, Expected to Vest	'	'	'	'	12,795
Intrinsic Value, Exercisable	'	'	'	'	$2,982

Stock_Based_Compensation_Expen2

Stock Based Compensation Expense - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

In Thousands, except Share data, unless otherwise specified

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Stock Options

Stock Options

Stock Options

Stock Options

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Performance Shares

Performance Shares

Performance Shares

Performance Shares

Performance Shares

Performance Shares

Performance Shares

Vested immediately

Vested immediately

Cliff Vest Four Hundred Fifty Days

Cliff Vest After Three Years

Cliff Vest After Three Years

Cliff Vest Ninety Days

Maximum

Performance based shares based upon net income and net sales for the period commencing April 1, 2013 and ending December 31, 2015

Performance based shares based upon AVD stock price appreciation over the course of the period commencing June 6, 2013 and ending on December 31, 2015

Cliff Vest After Three Years

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

'

'

'

$201

$236

$624

$668

$856

$589

$2,153

$1,188

'

'

'

'

'

'

$92

'

$118

'

'

'

'

Nonvested unamortized stock-based compensation expense, value

'

'

'

186

'

186

'

6,370

'

6,370

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Nonvested unamortized stock-based compensation expense, contractual term

'

'

'

'

'

'3 months 18 days

'

'

'

'2 years 1 month 6 days

'

'

'

'

'

'

'

'

'

'2 years 8 months 12 days

'

'

'

'

Number of Shares, Granted

4,500

8,230

145,884

'

'

'

'

'

'

158,614

247,536

'

'

'

'

'

'

'

24,637

'

'

'

'

24,637

Number of shares vested

5,000

8,230

'

'

'

'

'

'

'

13,230

99,992

8,230

13,352

'

'

'

'

'

'

'

'

'

'

'

Number of shares expected to vest

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500

148,884

227,184

7,000

'

'

'

'

'

'

'

Expenses recognized period

'

'

'

'

'

'

'

'

'

'

'

'

'

'450 days

'3 years

'3 years

'90 days

'

'

'

'

'

'

'3 years

Weighted Average Grant-Date Fair Value, Granted

$24.27

$30.19

$31.27

'

'

'

'

'

'

$31.06

$21.24

'

'

'

'

'

'

'

$30.13

'

'

$30.13

$15.31

'

Weighted Average Grant-Date Fair Value, Vested

$8.32

$30.37

'

'

'

'

'

'

'

$22.04

$14.13

'

'

'

'

'

'

'

'

'

'

'

'

'

Average vest date value Restricted share

'

'

'

'

'

'

'

'

'

$24.01

$19.29

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Shares, Forfeited

'

'

8,000

'

'

'

'

'

'

8,000

1,367

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Grant-Date Fair Value, Forfeited

'

'

$22.17

'

'

'

'

'

'

$22.17

$20.47

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of shares vesting based on Performance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80.00%

20.00%

'

Targeted performance percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200.00%

'

'

'

Unamortized stock-based compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$623

'

$623

'

'

'

'

Summary_of_NonVested_Shares_De

Summary of Non-Vested Shares (Detail) (USD $)	3 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of Shares, Beginning balance	383,701	383,701	245,817
Number of Shares, Granted	4,500	8,230	145,884
Number of Shares, Vested	-5,000	-8,230	'
Number of Shares, Forfeited	'	'	-8,000
Number of Shares, Ending Balance	383,201	383,701	383,701
Weighted Average Grant-Date Fair Value, Beginning balance	$24.87	$24.39	$20.23
Weighted Average Grant-Date Fair Value, Granted	$24.27	$30.19	$31.27
Weighted Average Grant-Date Fair Value, Vested	$8.32	$30.37	'
Weighted Average Grant-Date Fair Value, Forfeited	'	'	$22.17
Weighted Average Grant-Date Fair Value, Ending balance	$24.60	$24.87	$24.39
Performance Shares	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of Shares, Granted	'	24,637	'
Number of Shares, Ending Balance	24,637	24,637	'
Weighted Average Grant-Date Fair Value, Granted	'	$30.13	'
Weighted Average Grant-Date Fair Value, Ending balance	$30.13	$30.13	'

Legal_Proceedings_Additional_I

Legal Proceedings - Additional Information (Detail) (USD $)	9 Months Ended		1 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Sep. 19, 2013	Sep. 19, 2013	Oct. 16, 2013
	Other Matters	Former Banana Workers	Former Banana Workers	Former Banana Workers	Subsequent Event
	Brazil	Case	Delaware	Louisiana	Former Banana Workers
			Plaintiff	Plaintiff	Louisiana
					Plaintiff
Loss Contingencies [Line Items]	'	'	'	'	'
Number of lawsuits filed	'	100	'	'	'
Lawsuits filed in United States	'	15	'	'	'
Number of claimants	'	'	22	258	'
Number of dismissed complaints	'	'	14	'	235
Number of claimants involved	'	'	8	'	'
Fine assessed amount	$200	'	'	'	'
Loss contingency probable loss, minimum	200	'	'	'	'
Loss contingency probable loss, maximum	300	'	'	'	'
Loss contingency set up amount	$200	'	'	'	'

Cash_Flow_Hedge_Related_to_Var

Cash Flow Hedge Related to Variable Debt Instrument and Outstanding Foreign Currency Derivatives to Hedge Foreign Currency Balances Measured at Fair Value on Recurring Basis, and Balances (Detail) (Fair Value, Measurements, Recurring, Cash Flow Hedging, Level 2, USD $)	Sep. 30, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Measurements, Recurring | Cash Flow Hedging | Level 2	'		'
Liability:	'		'
Foreign currency derivative financial instrument	'		$160
Interest rate derivative financial instruments	$716	[1]	$1,201	[1]
[1]	Includes accrued interest expense

Beginning_Balance_Annual_Activ

Beginning Balance, Annual Activity and Ending Balance of each Component of Accumulated Other Comprehensive Income (Detail) (USD $)	3 Months Ended				9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'	'	'
Beginning Balance	($1,479)	($1,177)	($1,762)	'	($1,762)	'
Interest Rate Swap, Current period, other comprehensive income	133	174	178	41	485	87
Foreign currency translation, Current period, other comprehensive income	-126	-476	407	306	-195	428
Accumulated other comprehensive income, Current period, other comprehensive income	7	-302	585	'	'	'
Ending Balance	-1,472	-1,479	-1,177	'	-1,472	'
Interest Rate Swap	'	'	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'	'	'
Beginning Balance	-376	-550	-728	'	-728	'
Interest Rate Swap, Current period, other comprehensive income	133	174	178	'	'	'
Ending Balance	-243	-376	-550	'	-243	'
Accumulated Translation Adjustment	'	'	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'	'	'
Beginning Balance	-1,103	-627	-1,034	'	-1,034	'
Foreign currency translation, Current period, other comprehensive income	-126	-476	407	'	'	'
Ending Balance	($1,229)	($1,103)	($627)	'	($1,229)	'

Equity_Investment_Additional_I

Equity Investment - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013	Sep. 30, 2013
Equity Method Investments [Line Items]	'	'
Equity investment made	$3,687	$3,687
Equity investment ownership position	'	29.27%
Carrying value of equity investment	'	3,301
Quoted market value of equity investment	'	$4,288